Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1983;67:1290-1295

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hammerman, H.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammerman, H.
Right arrow Articles by Braunwald, E.

Circulation, Vol 67, 1290-1295, Copyright © 1983 by American Heart Association


ARTICLES

Indomethacin-induced scar thinning after experimental myocardial infarction

H Hammerman, RA Kloner, FJ Schoen, EJ Brown Jr, S Hale and E Braunwald

We investigated the effect of indomethacin, a widely used nonsteroidal antiinflammatory drug, on the healing of myocardial infarction (MI). Experimental MI was produced in anesthetized, open-chest dogs by occluding the left anterior descending coronary artery. Ten dogs received indomethacin, 10 mg/kg i.v., and 11 received saline, 15 minutes and 3 hours after occlusion. After 6 weeks, the dogs were killed and their hearts were subjected to morphologic and biochemical analysis. The average thickness of the transmural scar and the noninfarcted left ventricular wall was measured at multiple sites in formalin-fixed left ventricular slices and the ratio of the thickness of the transmural scar to the noninfarcted wall determined. The average thickness of the noninfarcted wall was 8.80 +/- 0.19 mm (mean +/- SEM) in the control group and 8.44 +/- 0.26 mm in the indomethacin group (NS). The scar thickness was 7.24 +/- 0.64 mm in the control group and 3.56 +/- 0.40 mm in the indomethacin group (p less than 0.001). The ratio of scar to noninfarcted wall thickness was 0.83 +/- 0.07 in the control group and 0.43 +/- 0.04 in the indomethacin group (p less than 0.001). Scars in treated dogs did not differ from controls either by light microscopic histologic analysis or by analysis of hydroxyproline content per unit weight. We conclude that indomethacin results in marked scar thinning when given early after experimental MI.


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
U. Landmesser, K. C. Wollert, and H. Drexler
Potential novel pharmacological therapies for myocardial remodelling
Cardiovasc Res, February 15, 2009; 81(3): 519 - 527.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. I. Jugdutt
Cyclooxygenase Inhibition and Adverse Remodeling During Healing After Myocardial Infarction
Circulation, January 23, 2007; 115(3): 288 - 291.
[Full Text] [PDF]


Home page
CirculationHome page
L. Timmers, J. P.G. Sluijter, C. W.J. Verlaan, P. Steendijk, M. J. Cramer, M. Emons, C. Strijder, P. F. Grundeman, S. K. Sze, L. Hua, et al.
Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig
Circulation, January 23, 2007; 115(3): 326 - 332.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. A. Lange and L. D. Hillis
Acute Pericarditis
N. Engl. J. Med., November 18, 2004; 351(21): 2195 - 2202.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Ohta, T. Nakajima, A. Y. L. Cheah, S. H. E. Zaidi, N. Kaviani, F. Dawood, X.-M. You, P. Liu, M. Husain, and M. Rabinovitch
Elafin-overexpressing mice have improved cardiac function after myocardial infarction
Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H286 - H292.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. W. Mahaffey, C. B. Granger, J. C. Nicolau, W. Ruzyllo, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, C. F. Mojcik, T. G. Todaro, et al.
Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial
Circulation, September 9, 2003; 108(10): 1176 - 1183.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. E. Khalil, E. N. Heller, F. Boctor, E. J. Brown Jr, and I. A. Alhaddad
Ventricular Free Wall Rupture in Acute Myocardial Infarction
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 231 - 236.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
R. Van Kerckhoven, E. A.J Kalkman, P. R Saxena, and R. G Schoemaker
Altered cardiac collagen and associated changes in diastolic function of infarcted rat hearts
Cardiovasc Res, May 1, 2000; 46(2): 316 - 323.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. G Schoemaker, P. R Saxena, and E. A.J Kalkman
Low-dose aspirin improves in vivo hemodynamics in conscious, chronically infarcted rats
Cardiovasc Res, January 1, 1998; 37(1): 108 - 114.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. H. Birdsall, D. M. Green, J. Trial, K. A. Youker, A. R. Burns, C. R. MacKay, G. J. LaRosa, H. K. Hawkins, C. W. Smith, L. H. Michael, et al.
Complement C5a, TGF-ß1, and MCP-1, in Sequence, Induce Migration of Monocytes Into Ischemic Canine Myocardium Within the First One to Five Hours After Reperfusion
Circulation, February 4, 1997; 95(3): 684 - 692.
[Abstract] [Full Text]